Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYCC Cyclacel Pharmaceuticals	$8.00 +9.3%	$7.71	$3.08 ▼ $597.60	$12.68M	0.08	746,549 shs	90,373 shs
MRKR Marker Therapeutics	$1.21 +4.3%	$1.47	$0.95 ▼ $5.95	$15.66M	1.45	541,261 shs	58,468 shs
NEUP Neuphoria Therapeutics	$6.92 -0.3%	$7.44	$2.12 ▼ $12.55	$13.01M	0.53	232,472 shs	22,204 shs
TTNP Titan Pharmaceuticals	$4.86 -0.2%	$4.42	$3.03 ▼ $9.00	$4.44M	1.29	38,551 shs	89,354 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYCC Cyclacel Pharmaceuticals	-2.27%	-17.75%	-37.22%	-66.58%	-97.54%
MRKR Marker Therapeutics	+2.65%	-10.08%	-24.18%	+2.65%	-68.82%
NEUP Neuphoria Therapeutics	-9.16%	-12.70%	-9.87%	+11.40%	+693,999,900.00%
TTNP Titan Pharmaceuticals	-3.82%	-2.49%	+8.16%	+6.86%	-50.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYCC Cyclacel Pharmaceuticals	1.0545 of 5 stars	0.0	4.0	0.0	2.1	2.5	0.0
MRKR Marker Therapeutics	3.6581 of 5 stars	3.8	2.0	3.9	2.6	0.0	0.0
NEUP Neuphoria Therapeutics	1.3519 of 5 stars	3.5	0.0	0.0	0.6	0.0	0.6
TTNP Titan Pharmaceuticals	0.3195 of 5 stars	0.0	3.0	0.0	2.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	988.15% Upside
NEUP Neuphoria Therapeutics	3.00	Buy	$21.00	203.47% Upside
TTNP Titan Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYCC Cyclacel Pharmaceuticals	$10K	1,268.00	N/A	N/A	$2.29 per share	3.49
MRKR Marker Therapeutics	$6.59M	2.38	N/A	N/A	$0.81 per share	1.49
NEUP Neuphoria Therapeutics	$10K	1,300.96	N/A	N/A	$15.85 per share	0.44
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	$3.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-723.64%	-145.51%	N/A
MRKR Marker Therapeutics	-$10.73M	-$1.37	N/A	N/A	N/A	-271.12%	-114.59%	-90.31%	N/A
NEUP Neuphoria Therapeutics	-$15.49M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/29/2025 (Estimated)
TTNP Titan Pharmaceuticals	-$4.71M	-$2.95	N/A	∞	N/A	N/A	-108.60%	-95.64%	8/21/2025 (Estimated)

Latest TTNP, NEUP, CYCC, and MRKR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	MRKR Marker Therapeutics	-$0.55	-$0.29	+$0.26	-$0.29	$0.72 million	$0.86 million
8/14/2025	Q2 2025	TTNP Titan Pharmaceuticals	N/A	-$0.65	N/A	-$0.65	N/A	N/A
8/13/2025	Q2 2025	CYCC Cyclacel Pharmaceuticals	-$72.00	-$0.98	+$71.02	-$0.98	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYCC Cyclacel Pharmaceuticals	$0.15	1.88%	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYCC Cyclacel Pharmaceuticals	N/A	5.77	5.60
MRKR Marker Therapeutics	N/A	3.45	6.79
NEUP Neuphoria Therapeutics	N/A	11.01	11.01
TTNP Titan Pharmaceuticals	N/A	11.60	7.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYCC Cyclacel Pharmaceuticals	23.58%
MRKR Marker Therapeutics	22.39%
NEUP Neuphoria Therapeutics	15.90%
TTNP Titan Pharmaceuticals	31.49%

Insider Ownership

Company	Insider Ownership
CYCC Cyclacel Pharmaceuticals	51.20%
MRKR Marker Therapeutics	7.80%
NEUP Neuphoria Therapeutics	0.69%
TTNP Titan Pharmaceuticals	0.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYCC Cyclacel Pharmaceuticals	14	1.59 million	773,000	Optionable
MRKR Marker Therapeutics	60	12.94 million	11.93 million	Not Optionable
NEUP Neuphoria Therapeutics	N/A	1.88 million	1.87 million	N/A
TTNP Titan Pharmaceuticals	10	914,000	907,000	Optionable

TTNP, NEUP, CYCC, and MRKR Headlines

Recent News About These Companies

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 304.7% in July

August 16, 2025 | americanbankingnews.com

TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP

August 5, 2025 | businesswire.com

URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)

July 29, 2025 | globenewswire.com

Titan Pharmaceuticals Inc (TTNP) - Investing.com

July 4, 2025 | investing.com

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - Morningstar

June 29, 2025 | morningstar.comM

Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - Nasdaq

June 29, 2025 | nasdaq.com

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

June 27, 2025 | finance.yahoo.com

Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management

June 27, 2025 | quiverquant.comQ

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

June 27, 2025 | globenewswire.com

titan pharmaceuticals issues common stock following preferred stock conversions

June 4, 2025 | investing.com

Titan announces filing of registration statement for proposed combination

June 4, 2025 | finance.yahoo.com

Titan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.

June 3, 2025 | quiverquant.comQ

Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

June 3, 2025 | globenewswire.com

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

April 11, 2025 | globenewswire.com

Titan Pharmaceuticals: Q4 Earnings Snapshot

March 20, 2025 | sfgate.com

Titan Pharmaceuticals receives Nasdaq notice of non-compliance

November 27, 2024 | markets.businessinsider.com

Titan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee Requirements

November 27, 2024 | quiverquant.comQ

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

November 27, 2024 | globenewswire.com

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

October 25, 2024 | msn.com

Titan Pharmaceuticals, Inc. (TTNP)

October 17, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTNP, NEUP, CYCC, and MRKR Company Descriptions

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.00 +0.68 (+9.29%)

Closing price 04:00 PM Eastern

Extended Trading

$8.04 +0.04 (+0.56%)

As of 05:17 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Marker Therapeutics NASDAQ:MRKR

$1.21 +0.05 (+4.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.20 -0.01 (-1.16%)

As of 04:23 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Neuphoria Therapeutics NASDAQ:NEUP

$6.92 -0.02 (-0.29%)

As of 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Titan Pharmaceuticals NASDAQ:TTNP

$4.80 -0.07 (-1.33%)

As of 04:00 PM Eastern

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time